Cerebrolysin
Porcine Brain-Derived Peptide Preparation
Mechanism of Action
Complex mixture of low-molecular-weight neuropeptides and free amino acids enzymatically derived from porcine brain protein. The low-MW peptide fraction crosses the blood-brain barrier and is proposed to exert multimodal neurotrophic-like activity (BDNF/NGF-mimetic signaling), reduce glutamate excitotoxicity, and have antioxidant/anti-inflammatory effects in neural tissue.
Key Benefits
- Improved cognitive function (MMSE, ADAS-cog+) in randomized trials for vascular dementia
- Improved global clinical functioning (CIBIC+) vs. placebo in the same trials
- No significant difference in adverse-event rates vs. placebo across pooled trial data
- Long-term compassionate-use case series report sustained function with repeat courses
Dosing Protocol
IV/IM only — the trial evidence base doesn't cover SubQ self-administration the way most of this library does. Cochrane rates the supporting evidence 'very low to low quality' due to small trial sizes and heterogeneity, even though the RCTs that exist show a real effect size. Treat as a real but modest signal, not a strong one.
Ideal Candidates
Research contexts modeling vascular cognitive decline or neurotrophic peptide mechanisms. Used clinically for dementia/stroke recovery in several countries — not an FDA-approved indication in the US.
Side Effects & Safety
Generally well-tolerated in published trials; infusion-site reactions, dizziness, and agitation have been reported. Cochrane's pooled analysis found no significant difference in adverse-event rates vs. placebo.
Regulatory Status
Gray AreaNot on the 503A bulks list. Gray zone — approved as a neurotrophic/nootropic drug in Russia, Eastern Europe, and parts of Asia; not FDA-approved in the US. IV/IM administration, not a self-inject SubQ peptide.
Evidence & Citations
How we source and weigh evidence- Cui S, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;2019(11):CD008900.
- Guekht AB, et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. 2010;20(4):310-8.
- Molloy DW, Standish TI. Clinical experience with Cerebrolysin. J Neural Transm Suppl. 2000;59:293-300.
Frequently asked
What is Cerebrolysin?+
Cerebrolysin (Porcine Brain-Derived Peptide Preparation) is a peptide studied for neurotrophic and cognitive support. Complex mixture of low-molecular-weight neuropeptides and free amino acids enzymatically derived from porcine brain protein. The low-MW peptide fraction crosses the blood-brain barrier and is proposed to exert multimodal neurotrophic-like activity (BDNF/NGF-mimetic signaling), reduce glutamate excitotoxicity, and have antioxidant/anti-inflammatory effects in neural tissue.
What is the dosing protocol for Cerebrolysin?+
Literature commonly references 10 mL/day IV (shorter research protocols) (low) to 20–30 mL/day IV (per published RCT dosing) (maintenance) via IV / IM, on a 10–20 day iv course, repeated periodically in published protocols cycle. Educational reference only — a licensed Stackhaus Health provider sets any personalized protocol.
What is the regulatory status of Cerebrolysin?+
Not on the 503A bulks list. Gray zone — approved as a neurotrophic/nootropic drug in Russia, Eastern Europe, and parts of Asia; not FDA-approved in the US. IV/IM administration, not a self-inject SubQ peptide.
Where can I access Cerebrolysin?+
Research-grade Cerebrolysin is available through Stackhaus Research. For a personalized, provider-reviewed protocol, consult a licensed clinician through Stackhaus Health.